Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer

详细信息    查看全文

• 作者：Hideomi Yamashita ; Akihiro Haga ; Ryousuke Takenaka ; Tomoki Kiritoshi…
• 关键词：Esophageal cancer ; Definitive chemoradiotherapy ; Nedaplatin ; S ; 1
• 刊名：Radiation Oncology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：11
• 期：1
• 全文大小：734 KB
• 参考文献：1.Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, et al. Phase I study and pharmacological analysis of cis-diammine (glycolato) platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. Cancer Res. 1991;51:1472–7.PubMed
  2.Uchida N, Takeda Y, Hojo K, Maekawa R, Sugita K, Yoshioka T, et al. Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model. Eur J Cancer. 1998;34:1796–801.PubMed CrossRef
  3.Yoshioka T, Gamoh M, Shineha R, Ishibashi S, Shibata H. A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers. Intern Med. 1999;38:844–8.PubMed CrossRef
  4.Yamashita H, Nakagawa K, Tago M, Igaki H, Nakamura N, Shiraishi K, et al. Radiation therapy combined with cis-diammine-glycolatoplatinum (nedaplatin) and 5-fluorouracil for Japanese stage II–IV esophageal cancer compared with cisplatin plus 5-fluorouracil regimen: a retrospective study. Dis Esophagus. 2006;19:15–9.
  5.Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two chemical modulators. Anticancer Drugs. 1996;7:548–57.PubMed CrossRef
  6.Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, et al. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemothe Pharmacol. 1997;39:205–11.CrossRef
  7.Hirata K, Horikoshi N, Aibe K, Okazaki M, Denno R, Sasaki K, et al. Phamacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res. 1999;5:2000–5.PubMed
  8.Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000;58:191–7.PubMed CrossRef
  9.Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer. 2003;89:2207–12.PubMed PubMedCentral CrossRef
  10.Sato Y, Kondo H, Honda K, Takahari D, Sumiyoshi T, Tsuji Y, et al. A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen. Int J Clin Oncol. 2005;10:40–4.PubMed CrossRef
  11.Nakata B, Mitachi Y, Tsuji A, Yamamitsu S, Hirata K, Shirasaka T, et al. Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902). Clin Cancer Res. 2004;10:1664–9.PubMed CrossRef
  12.Yamashita H, Kida S, Sakumi A, Haga A, Ito S, Onoe T, et al. Four-dimensional measurement of the displacement of internal fiducial markers during 320-multislice computed tomography scanning of thoracic esophageal cancer. Int J Radiat Oncol Biol Phys. 2011;79:588–95.PubMed CrossRef
  13.Yamashita H, Omori M, Takenaka R, Okuma K, Kobayashi R, Ohtomo K, et al. Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of 18FDG-PET scans: A phase II study. Radiother Oncol. 2014;113:182–7.PubMed CrossRef
  14.Yamashita H, Nakagawa K, Tago M, Nakamura N, Shiraishi K, Ohtomo K. Salvage radiotherapy for postoperative loco-regional recurrence of esophageal cancer. Dis Esophagus. 2005;18:215–20.PubMed CrossRef
  15.Kobayashi R, Yamashita H, Okuma K, Shiraishi K, Ohtomo K, Nakagawa K. Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer. Dis Esophagus. 2014;27:72–8.PubMed CrossRef
  16.Sobin LH, Gospodarowicz MK, Wittekind C. editors. TNM classification of malignant tumours. New York: John Wiley and Sons, Inc; 2009.
  17.Hsu CH, Yeh KH, Lui LT, Lee YC, Bu CF, Wang HP, et al. Concurrent chemoradiotherapy for locally advanced esophageal cancer – a pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil. Anticancer Res. 1999;19:4463–7.PubMed
  18.Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.PubMed
  19.Murakami M, Kuroda Y, Nakajima T, Okamoto Y, Mizowaki T, Kusumi F, et al. Comparison between chemoradiation protocol intended for organ preservation and conventional surgery for clinical T1–T2 esophageal carcinoma. Int J Radiat Oncol Biol Phys. 1999;45:277–84.PubMed CrossRef
  20.Stahl M, Mariette C, Haustermans K, Cervantes A, Arnold D, Guidelines Working Group ESMO. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi51–6.PubMed CrossRef
  21.van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.PubMed CrossRef
  22.Tanaka Y, Yoshida K, Osada S, Yamaguchi K, Takahashi T. Docetaxel, nedaplatin, and S-1 (DGS) chemotherapy for advanced esophageal carcinoma: a phase I dose-escalation study. Anticancer Res. 2011;31:4589–97.PubMed
  23.Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.PubMed CrossRef
  24.Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21:2697–702.PubMed CrossRef
  
• 作者单位：Hideomi Yamashita (1)
  Akihiro Haga (1)
  Ryousuke Takenaka (1)
  Tomoki Kiritoshi (1)
  Kae Okuma (1)
  Kuni Ohtomo (1)
  Keiichi Nakagawa (1)
  
  1. Department of Radiology, University of Tokyo Hospital of Bunkyo-ku, Tokyo, Japan
  
• 刊物主题：Oncology; Radiotherapy;
• 出版者：BioMed Central
• ISSN：1748-717X

文摘

Background Standard chemoradiotherapy (CRT) using cisplatin (CDDP) and 5-fluorouracil (5-FU) is an optional treatment for patients with stage II-III esophageal cancer. However, there are some demerits in this regimen because CDDP administration requires a large transfusion volume and 5-FU must be continuously infused over 24 h. Therefore, hospitalization is unavoidable. We collected retrospectively the data of definitive CRT with nedaplatin and S-1 as carried out in our institution.